Journal
CANCER LETTERS
Volume 231, Issue 1, Pages 20-29Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2005.01.006
Keywords
differentiation therapy; DU145; IMPDH inhibitors; mycophenolic acid; mycophenolate mofetil; prostate cancer
Categories
Funding
- NCI NIH HHS [CA 80826] Funding Source: Medline
Ask authors/readers for more resources
Inosine 5'-monophosphate dehydrogenase inhibitors including mycophenolic acid (MPA) are effective inducers of terminal differentiation in a variety of distinct human tumor cell types. Here, we report that MPA also induces such a differentiation in the androgen-independent prostate cancer derived cell line DU145. MPA evoked replication arrest and accumulation of the DU145 cells in the S-phase of the cell cycle. The inhibitor also induced the expression of CD55, clusterin, granulophysin, glucose-regulated protein 78, vasoactive intestinal polypeptide and prostate-specific transglutaminase, which are differentiation markers associated with the phenotype of normal prostate cells. We suggest that inosine 5'-monophosphate dehydrogenase inhibitors, which are already used for the treatment of other diseases, may be used as potential differentiation therapy drugs to control prostate cancer. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available